Patient characteristics of patients who started with lenalidomide
| Patient characteristic . | Value . |
|---|---|
| Total no. | 30 |
| Male/female | 19/10 |
| Median age, y (range) | 53 (37-65) |
| WHO performance status 0/1/2 | 20/9/1 |
| ISS stage at diagnosis I/II/III | 9/11/10 |
| Induction therapy before HDM | |
| VAD/TAD/PAD | 17/4/9 |
| Conditioning NMA allo-SCT | |
| TBI/TBI + fluda/TBI + fluda + ATG | 28/1/1 |
| Median CD34+-infused stem cells, × 106/kg (range) | 5.9 (2.0-10.9) |
| Median time between allo-SCT and start of lenalidomide, wk (range) | 12 (4-27) |
| Patient characteristic . | Value . |
|---|---|
| Total no. | 30 |
| Male/female | 19/10 |
| Median age, y (range) | 53 (37-65) |
| WHO performance status 0/1/2 | 20/9/1 |
| ISS stage at diagnosis I/II/III | 9/11/10 |
| Induction therapy before HDM | |
| VAD/TAD/PAD | 17/4/9 |
| Conditioning NMA allo-SCT | |
| TBI/TBI + fluda/TBI + fluda + ATG | 28/1/1 |
| Median CD34+-infused stem cells, × 106/kg (range) | 5.9 (2.0-10.9) |
| Median time between allo-SCT and start of lenalidomide, wk (range) | 12 (4-27) |
WHO indicates World Health Organization; ISS, International Staging System; HDM, high-dose melphalan; VAD, vincristine, adriamycin, and dexamethasone; TAD, thalidomide, adriamycin, and dexamethasone; PAD, bortezomib, adriamycin, and dexamethasone; TBI total body irradiation; and fluda, fludarabine.